Table 2.
Data | Values | n |
---|---|---|
Age (year) | 59(M) | 56 |
59 (Med) | ||
28–89 | ||
G (F)% | 73.2 | 56 |
Underlying disease (%) | ||
RA | 42.8 | 56 |
SLE | 26.8 | |
ORD | 17.8 | |
Misc | 12.6 | |
Drug % | ||
CQ | 58.9 | 56 |
HQC | 41 | |
DD(mg/d) | 393(M) | 56 |
400(Med) | ||
DT(m) | 37(QC) | 56 |
24(HCQ) | ||
PW/CW/Dys (%) | 87.2/17.8/8.9 | 56 |
Elevated CK %/M/Med | 60.7/613/339 | 34 |
RD % | 12.5 | 56 |
EMG % | ||
Myop | 54 | 50 |
Neuromyo | 16 | |
N | 2 | |
Muscle biopsy % | ||
Vacuolar | 53.7 | 54 |
NSF | 46.2 | |
MB (EM) % | ||
CB | 86.8 | 38 |
MB | 8 | |
Impr/death (%) | 85.4/12.7 | 55 |
M, mean; Med, median; y, year; G, gender; F, female; CQ, chloroquine; HCQ, hydroxychloroquine; DD, daily dose; DT, duration treatment; m, months; PW, proximal weakness; CW, cervical weakness; Dys, dysphagia; OM, optic microscopy; EM, electron microscopy; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; ORD, other rheumatic diseases; Misc, miscellaneous; CQ, chloroquine; HQC ORD, other rheumatic disorders; CK, creatine kinase; RD, respiratory distress; Myop, myopathic; Neuromyo, neuromyopathic; N, neuropathy; NSF, no specific findings; CB, curvilinear bodies; MB, myeloid bodies; Impr, improvement